Page 8 - Nuclear Export News Today

Fox Run Management L.L.C. purchased a new position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 28,823 shares of the company’s stock, valued at approximately $98,000. A number of other hedge funds have […]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 17,760,000 shares, a decline of 7.0% from the March 31st total of 19,090,000 shares. Based on an average trading volume of 2,350,000 shares, the […]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 17,760,000 shares, a decline of 7.0% from the March 31st total of 19,090,000 shares. Based on an average daily trading volume, of 2,350,000 shares, […]

– Relapsed/Refractory MDS Patients Achieved Median Overall Survival of 8.7 months – –  Historically, Median Overall Survival in this Hard to Treat Patient Population is Only... | May 3, 2023

NEWTON, Mass., May 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an... | May 1, 2023

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) EVP Reshma Rangwala sold 6,770 shares of the business’s stock in a transaction on Thursday, April 20th. The shares were sold at an average price of $4.05, for a total transaction of $27,418.50. Following the transaction, the executive vice president now directly owns 158,230 shares of the company’s […]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 19,090,000 shares, a growth of 14.1% from the March 15th total of 16,730,000 shares. Based on an average daily trading volume, of 2,600,000 shares, the days-to-cover ratio […]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) – Equities researchers at Wedbush lifted their Q1 2023 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a research note issued on Wednesday, April 19th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.34) for the quarter, up […]

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The […]

– At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in Efficacy Evaluable Population, 79% SVR35 and 58% TSS50 in...